Mizuho Securities USA LLC Buys 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mizuho Securities USA LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 625.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 59,341 shares of the biopharmaceutical company's stock after buying an additional 51,162 shares during the period. Mizuho Securities USA LLC owned 0.05% of Regeneron Pharmaceuticals worth $62,382,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the second quarter worth $26,000. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 3.3 %

NASDAQ:REGN traded down $25.70 during mid-day trading on Friday, hitting $756.81. The company had a trading volume of 1,374,549 shares, compared to its average volume of 530,457. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $753.69 and a fifty-two week high of $1,211.20. The firm has a market cap of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. The business's fifty day moving average is $985.21 and its two-hundred day moving average is $1,032.97.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on REGN shares. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 22nd. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday. They set an "outperform" rating and a $1,150.00 target price for the company. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Finally, Barclays cut their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.